# Pulmonary Hypertension: Let’s Take Stock!

## TL;DR

This review summarizes the classification, causes, diagnosis, and treatment of pulmonary hypertension, emphasizing the importance of expert care for better patient outcomes.

## Contribution

The paper offers a comprehensive and up-to-date review of pulmonary hypertension, focusing on classification, pathophysiology, and treatment advancements.

## Key findings

- PH is classified into five clinical groups with PAH as a severe subset defined by specific hemodynamic criteria.
- Current treatments target endothelin, nitric oxide, and prostacyclin pathways, with novel therapies under investigation.
- Expert centers are essential for accurate diagnosis, multidisciplinary care, and clinical trial enrollment.

## Abstract

Pulmonary hypertension (PH) encompasses a group of conditions characterized by elevated pulmonary arterial pressure, with pulmonary arterial hypertension (PAH) representing a distinct and severe subset. This review provides a comprehensive overview of the current classification system, highlighting the five clinical groups of PH and the specific hemodynamic criteria defining PAH. We discuss the complex pathophysiological mechanisms underlying PAH, including vascular remodeling, endothelial dysfunction, and genetic predisposition. Advances in diagnostic approaches are explored. Current treatment strategies targeting key molecular pathways such as endothelin, nitric oxide, and prostacyclin are reviewed alongside novel and investigational therapies. Prognostic indicators and risk stratification tools are evaluated to guide clinical management. Finally, we underscore the critical role of expert centers in accurate diagnosis, multidisciplinary care, and enrollment in clinical trials, which collectively improve patient outcomes in this challenging disease spectrum.